Characterization of the DNA binding specificity of Shelterin complexes by Choi, Kyung H. et al.
Characterization of the DNA binding specificity
of Shelterin complexes
Kyung H. Choi
1, Amy S. Farrell
2, Amanda S. Lakamp
1 and Michel M. Ouellette
1,3,*
1Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, NE 68198,
2Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland,
OR, 97239 and
3Department of Biochemistry and Molecular Biology, University of Nebraska
Medical Center, Omaha, NE 68198, USA
Received May 12, 2011; Revised July 27, 2011; Accepted July 28, 2011
ABSTRACT
The Shelterin complex associates with telomeres
and plays an essential role in telomere protection
and telomerase regulation. In its most abundant
form, the complex is composed of six core compo-
nents: TRF1, TRF2, POT1, TIN2, TPP1 and RAP1. Of
these subunits, three can interact directly with
either single-stranded (POT1) or double-stranded
(TRF1, TRF2) telomeric DNA. In this report, we
have developed assays to measure the DNA
binding activity of Shelterin complexes in human
cell extracts. With these assays, we have
characterized the composition and DNA binding
specificity of two Shelterin complexes: a
6-member complex that contains all six core com-
ponents and a second complex that lacks TRF1. Our
results show that both of these complexes bind with
high affinity (KD=1.3–1.5 10
 9 M) and selectively to
ds/ss-DNA junctions that carry both a binding site
for POT1 (ss-TTAGGGTTAG) and a binding site for
the SANT/Myb domain of TRF1 or TRF2 (ds-TTAGGG
TTA). This DNA binding specificity suggests the
preferential recruitment of these complexes to
areas of the telomere where ss- and ds-DNA are in
close proximity, such as the 30-telomeric overhang,
telomeric DNA bubbles and the D-loop at the base
of T-loops.
INTRODUCTION
Telomeres are essential structures that cap and protect the
ends of linear chromosomes. Telomeres hide chromosom-
al ends from DNA damage sensing mechanisms and
the DNA repair machinery (1,2) (http://www.els.net/).
When telomeres become dysfunctional, ends are sensed
as double-stranded DNA breaks (ds-DNA breaks).
This recognition results in the activation of DNA
damage checkpoints that trigger senescence or apoptosis
as well as attempts by the cells to repair the ends by non-
homologous end-joining (NHEJ), a process that creates
interchromosomal fusions. The protective function of
telomeres is mediated by the activities of telomere-
associated protein complexes and by the T-loops (3,4).
Telomeres are made of tandem copies of a simple DNA
repeat, (TTAGGG)n, which the enzyme telomerase syn-
thesizes (5,6). Most of the telomere is composed of
duplex telomeric DNA with the exception of the last
50–500 bases of the G-rich strand, which forms a
single-stranded 30-telomeric overhang (1,2). Evidence
suggests that this 30-overhang is sequestered into a large
lariat structure, termed the T-loop (3,7). Formation of this
structure is presumed to involve the insertion of the
30-telomeric overhang into duplex telomeric DNA, its hy-
bridization with the C-rich strand, and dislodgment of the
G-rich strand into a displacement loop (D-loop). It has
been proposed that T-loops are especially well-adapted to
shield the ends of chromosomes from DNA repair and
DNA damage-sensing mechanisms (3,7). Several DNA
binding proteins interact selectively with telomeric DNA
and localize to telomeres. TRF1 and TRF2 (Telomeric
Repeat Factors 1 and 2) recognize duplex telomeric
DNA whereas POT1 (Protection of Telomere 1) associates
with the ss-telomeric DNA present at the 30-overhang and
in the D-loop (8,9). Via protein–protein interactions, these
DNA binding factors bring a number of other proteins to
telomeres, where they localize to form a variety of
complexes (1,10). Among these complexes is the
Shelterin/Telosome complex, which plays a key role in
telomere capping and telomerase regulation.
The Shelterin/Telosome complex brings the three telo-
meric DNA binding factors (TRF1, TRF2 and POT1)
together in the same large complex (4,10–12). In its most
abundant form, the complex is composed of six core com-
ponents: TRF1, TRF2, POT1, TIN2, TPP1 and RAP1.
The scaffolding subunit TIN2 binds simultaneously to
*To whom correspondence should be addressed. Tel: +1 402 559 5556; Fax: +1 402 559 4651; Email: mouellet@unmc.edu
9206–9223 Nucleic Acids Research, 2011, Vol. 39, No. 21 Published online 18 August 2011
doi:10.1093/nar/gkr665
 The Author(s) 2011. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.TRF1, TRF2 and TPP1, whereas TPP1 connects POT1
with TIN2 (11,13–18). A sixth component, RAP1, is a
TRF2-associated factor (19). In addition to this
6-member complex, Shelterin may also be present in the
form of sub-complexes that lack either TRF1 or TRF2/
RAP1 (10,12,17,20–25). While the importance of these dif-
ferent sub-complexes remains unclear, the particular
function of each of the three DNA binding subunits
(TRF1, TRF2 and POT1) is well-understood. For
example, POT1 serves to hide the 30-telomeric overhang
from telomerase and from DNA damage sensing mechan-
isms. Hence, the loss of POT1 leads to the activation
of the ATR kinase, formation of telomere
dysfunction-induced foci (TIFs), and induction of either
apoptosis or cell cycle arrest (22,26–28). In cells that lack
functional checkpoints, POT1 dysfunction leads to a loss
of telomerase regulation that results in longer telomeres
(18,29). The same effects, along with the loss of telomeric
POT1, have been observed in cells expressing POT1
mutants that fail to interact with TPP1 or after depletion
of TRF1, TPP1 or TIN2 (10,13–16,18,22,29–32). These
observations are consistent with the idea that POT1
performs its functions as part of the Shelterin complex.
On the other hand, TRF2 serves to block recognition of
telomeres as ds-DNA breaks. Loss of TRF2 function leads
to the activation of the ATM kinase, formation of TIFs,
and induction of either senescence or apoptosis
(20,26,33–36). In cells lacking functional checkpoints,
telomeres devoid of TRF2 serve as substrates for NHEJ
and give rise to interchromosomal fusions (25,37). TRF2
also appears to be important for the formation and main-
tenance of T-loops. In vitro studies have shown that
puriﬁed TRF2 can promote the folding of artiﬁcial telo-
meres into T-loop structures, a property not displayed by
TRF1 (7,38). Amiard et al. (39) have described properties
of TRF2 that may explain its ability to form T-loops.
Their results show that DNA is positively supercoiled by
the binding of TRF2 but not TRF1. In rotationally re-
stricted duplex DNA molecules, this energy was released
by the untwisting of ﬂanking DNA, a process that made
the untwisted strands available for hybridization to
ss-telomeric DNA probes (39). At the telomeres, this un-
twisting of the DNA helix at sites ﬂanking TRF2 could
promote invasion by the 30-telomeric overhang. TRF2
also appears to be important for T-loop stability. As
recently demonstrated by Fouche et al. (40), the
N-terminal basic domain of TRF2 (amino acids 1–44)
binds ss-DNA in a sequence-independent manner and
can associate with a multitude of DNA topologies,
including 3-way and 4-way junctions, model replication
forks, chickenfoot structures and ds/ss-junctions.
Expression of a TRF2 mutant that lacks this domain
results in catastrophic deletions of T-loops through what
appears to be XRCC3-mediated homologous recombin-
ation (41). Based on these observations, it has been
proposed that TRF2 protects telomeres, at least in part,
through its ability to promote T-loop formation (3,7).
However, what is still unclear is whether these many func-
tions are all being accomplished by TRF2 in the context of
the Shelterin complex. One confounding factor is the
evidence that TRF2 may be part of other complexes as
well. A recent study has found isolated chromatin to
contain a vast molar excess of TRF2, TIN2 and RAP1
compared to TRF1, TPP1 and POT1, thereby raising the
possibility of a separate TRF2/RAP1/TIN2 complex (24).
Moreover, the effects of TRF2 depletion were not
recapitulated by the loss of the other Shelterin compo-
nents TRF1, TPP1 or POT1 (10,18,22,26,29–32). Hence,
it may be that telomeres are populated by Shelterin
complexes and by other TRF1- and TRF2-containing
complexes, each performing their own distinct functions.
Among telomere-associated complexes, Shelterin
complexes are unique in that they bring together the
DNA binding activities of POT1, TRF1 and TRF2. This
arrangement most certainly provides these complexes with
their own unique mode of interaction with the telomere,
the understanding of which should shed light on how and
where these complexes function at the telomere. Current
models of the interactions of these complexes with the
telomere are extrapolated from the well-characterized
DNA binding properties of recombinant TRF1, TRF2
and POT1. Recombinant POT1 binds with high afﬁnity
(KD=9.5nM) to single-stranded 50-TTAGGGTTAG-30
by means of two oligonucleotide/oligosaccharide binding
(OB) folds (8,42,43). As shown by X-ray crystallography,
the ﬁrst OB-fold (OB1) interacts with 50-TTAGGG
whereas the second fold (OB2) associates with down-
stream TTAG-30 (43). TRF2 and TRF1 share the same
basic architecture deﬁned by two conserved regions: a
TRFH domain that mediates homodimerization and a
carboxy-terminal DNA binding domain of the SANT/
Myb family (9). The two factors give rise to homodimers
that bind selectively to ds-telomeric DNA (9,44). As
determined by SELEX (systematic evolution of ligands
by exponential enrichment) and electrophoretic mobility
shift assays, telomeric DNA recognition by TRF1 dimers
requires two copies of an YTAGGGTTR motif (Y=C/T,
R=A/G), which the dimer can recognize without con-
straints on either spacing or orientation (45). This ﬂexibil-
ity has been attributed to the ﬂexible hinge region that
separates the dimerization and DNA binding domains.
While the interactions of TRF1, TRF2 and POT1 with
DNA have been extensively investigated, how these
factors combine to dictate the DNA binding properties
of Shelterin complexes remains poorly understood.
Shelterin complexes are most often depicted as being
bound to tracks of ds-telomeric DNA, and in some
cases with POT1 interacting simultaneously with the
30-telomeric overhang. Yet, the modes of interaction of
these complexes with the telomere, their DNA binding
afﬁnity and speciﬁcity are still very poorly deﬁned.
Major shortfalls have been the inability to reconstitute
these complexes in vitro using puriﬁed recombinant
proteins and the lack of an assay to detect the activity
of the native complexes in cell extracts.
In this article, we describe an electrophoretic mobility
shift assay and a pulldown assay which allow detection of
the DNA binding activity of Shelterin complexes in
human cell extracts. With these assays, we have
characterized the composition and DNA binding speciﬁ-
city of Shelterin complexes present in HeLa and HT1080
cell extracts. Our results show that these complexes bind
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site for POT1 and a binding site for the Myb domain of
TRF1 or TRF2. This binding speciﬁcity would be
expected to recruit these complexes to regions of the
telomere where ss- and ds-DNA are in close proximity,
such as the 30-telomeric overhang, telomeric DNA
bubbles, and the D-loop at the base of T-loops.
MATERIALS AND METHODS
Materials
Oligonucleotides were synthesized by the Eppley Core
Facility (University of Nebraska Medical Center,
Omaha, NE, USA) or Integrated DNA Technologies
Inc. (Coralville, IA, USA). Plasmids
pTetFLAGhTRF2
45-501 (25) and pTethTRF1 (31) were
gifts from Dr Titia de Lange (Rockefeller University,
New York, NY, USA). Restriction enzyme PpiI was
purchased from Fermentas (Hanover, MD, USA),
whereas HgaI and MlyI were obtained from New
England BioLabs (Beverly, MA, USA). Unless otherwise
speciﬁed, all other enzymes were either from Invitrogen
(Carlsbad, CA, USA) or Promega (Madison, WI, USA).
g-[
32P]-ATP was obtained from MP Biologicals (Solon,
OH, USA). DMEM, Trypsin–EDTA, Penicillin/
Streptomycin and Lipofectamine 2000 were from
Invitrogen. Fetal bovine serum, Transferrin and
Microcystin-LR were from HyClone (Logan, UT, USA),
Collaborative Biomedical Products (Bedford, MA, USA)
and Cayman Chemical (Ann Arbor, MI, USA), respect-
ively. Mammalian protease inhibitor cocktail (cat #
P8340), 3XFLAG peptide and all other chemicals were
from Sigma-Aldrich (St Louis, MO, USA). M-450
magnetic beads coated with a Sheep anti-Mouse IgG
antibody were purchased from Dynal Biotech. Inc.
(Lake Success, NY, USA).
Antibodies and western blot analysis
Western blot analyses were performed as described previ-
ously (46). Mouse monoclonal antibodies used in western
blots were against the Flag tag (M2, Stratagene, La Jolla,
CA, USA) and TPP1 (1D8-1B6, Novus Biologicals).
Rabbit polyclonal antibodies were against TRF2 (H-300,
Santa Cruz Biotech.), TRF1 (ab1423, Abcam Inc.), RAP1
(A300-306A, Bethyl Lab. Inc.) and Actin (I-19, Santa
Cruz Biotech.). Antibodies used for supershifts were the
same as above plus antibodies against TIN2 (mouse
monoclonal 59B388, Abcam Inc.), POT1 (rabbit poly-
clonal IMG-5343A, IMGENEX), Vimentin (mouse
monoclonal sc-6260, Santa Cruz Biotech.) and c-Fos
(mouse monoclonal sc-047, Santa Cruz Biotech).
Normal IgG from rabbit and mouse were purchased
from Calbiochem and Santa Cruz Biotech, respectively.
siRNA transfections
siGENOME ON-TARGETplus SMARTpool duplexes
directed against the human TPP1 (L-014237), TIN2
(L-019951), POT1 (L-004205) and TRF1 (L-010542)
mRNAs, as well as the non-targeting SMARTpool
(D-001810-10), were from Dharmacon (Lafayette, CO,
USA). HT1080-TRF2 cells were transfected with the dif-
ferent SMARTpool using DharmaFECT1 transfection
reagent, according to Dharmacon’s instructions.
Seventy-two hours following transfection, nuclear
extracts were prepared as described below and total
RNA was isolated using the TRIzol reagents
(Invitrogen) following the manufacturer’s instructions.
Real-time qPCR
Real-time PCR quantiﬁcation of the GAPDH, TRF2,
TRF1, TPP1, TIN2 and POT1 mRNA was performed
using a SmartCycler System (Cepheid, Sunnyvale, CA,
USA). Reverse Transcriptions were done as described pre-
viously using the SuperScript III Reverse Transcriptase
(Invitrogen, Carlsbad, CA) (46). The cDNA generated
was subjected to SYBR green qPCR on the Cepheid
SmartCycler using software version 2.0c. Gene expres-
sion was assayed using RT
2 Real-TimeTM SYBR Green
PCR master mix from SA BioSciences (Frederick, MD,
USA) according to the manufacturer’s protocol using
PCR primers for GAPDH (50-AGGTCGGTGTGAACG
GATTTG-30 and 50-TGTAGACCATGTAGTTGAGGT
CA-30), TRF2 (50-AGACTTGGGTGGAAGAGGA-30
and 50-TAATCATCACAGCTGTTCGG-30), TRF1 (50-T
CTGCGGTAACTGAATCCTC-30 and 50-GTTACCGG
CTGACTCTTTGA-30), TPP1 (50-GGGAGGACCAGG
AGCAT-30 and 50-GGGCCTAGAGAGCTCAGAAT-30),
TIN2 (50-TTGCCTGGAGACAATATGGT-30 and 50-G
TCGGCCAGCTAGAGGTT-30) and POT1 (50-TGTGG
CAAGATCTCTGAAGG-30 and 50-TCTGAATGCTGA
TTGGCTGT-30). To quantify differences in gene expres-
sion, all experiments were designed to include a standard
curve of a serially diluted pool made of all cDNAs. For
each siRNA SMARTpool transfected, levels of the
targeted mRNA and of the TRF2 and GAPDH mRNAs
were measured, comparing the targeted cells to those
transfected with the non-targeting SMARTpool. For
each mRNA, expression in the targeted cells was
reported as a fraction of that observed in the control
cells transfected with the non-targeting siRNA, with the
later arbitrarily set to a value of 1.
Expression vectors
Plasmids pcDNA3.1-Flag-TRF2
B and pcDNA3.1-
Flag-TRF2 were made from their pCMV1 equivalents,
by transfer of their TRF2 cassettes to vector
pcDNA3.1(–) (Invitrogen). pCMV1-Flag-TRF2
B was
made by the transfer of a SacII–BamHI fragment from
plasmid pTetFLAGhTRF2
45-501 (a gift from Titia de
Lange, Rockefeller University, NY, USA) (25) to
pCMV1. To generate pCMV-Flag-TRF2, plasmid
pCMV-Flag-TRF2
B was cut with EcoRI (between the
Flag tag and TRF2
B) and with SacI (within TRF2
B)
to replace the N-terminus of TRF2
B with an EcoRI/
SacI-digested PCR product ampliﬁed from pCMV-
SPORT6-TRF2 (Open Biosystem, BC024890 encoding
full-length TRF2) using a T7 primer and primer
50-CCGGAATTCGGTGGAATGGCGGGAGGAGGC
GGGAGT-30 (underlined EcoRI site in frame with the
9208 Nucleic Acids Research, 2011,Vol.39, No. 21Flag tag). pcDNA3.1-Flag-TRF2
B(R361P) was made
by site-directed mutagenesis of pcDNA3.1-Flag-TRF2
B
with the Quick Change II XL kit (Stratagene) using 50-GC
AGCCCAAGAACAAGCGCATGACAATAAGCCCAT
TGGTCTTGGAGGAGGACAGCCAGAGTACTGAG
-30 (mutated positions underlined) and its complementary
oligo. pcDNA3.1-TRF2
B was generated by the
insertion into the BamHI/XhoI sites of pcDNA3.1(+) of
a BamHI/SalI-digested TRF2
B cassette ampliﬁed
from pcDNA3.1-Flag-TRF2
B using primers 50-CTCGG
ATCCACCATGGCACGGCTGGAAGAGGCAGTCA
ATC-30 and 50-GGAATTCGTCGACTCAGTTCATGC
CAAGTCTTTTCAT-30 (BamH1 and Sal1 sites
underlined). pcDNA3.1-Flag–TIN2 plasmid was a deriva-
tive of plasmid pOTB7-TIN2 (Open Biosystem) encoding
the longer isoform of TIN2 (NP_001092744). Brieﬂy,
TIN2’s open reading frame was PCR ampliﬁed with
Platinum Pfx DNA polymerase (Invitrogen) using
primer Tin2-F (50-CCGGAATTCATGGCTACGCCCC
TGGTGGCG-30, EcoRI site underlined) and Tin2-R
(50-CGCGGATCCTCACTCCTTTTGCTCTGTGGCAG
GCAA-30). EcoRI-digested product was inserted in
EcoRI/PmeI sites of plasmid pcDNA3.1-Flag, in frame
with the Flag tag. pcDNA3.1-Flag is a pcDNA3.1(–)
vector encoding a Flag epitope located downstream of a
T7 promoter and followed by an EcoRI site.
HT1080-TRF2 and HT1080-Vector cells
HT1080 cells were cultured in DMEM supplemented
with 10% fetal bovine serum and 100U/ml penicillin/
streptomycin. Subconﬂuent HT1080 cells were transfected
with pcDNA3.1-Flag-TRF2 by transferrin-facilitated
lipofection, as described previously (47). Transfected
cells were selected with 400mg/ml G418 and individual
colonies isolated by means of cloning rings. Using the
M2 anti-Flag antibody, colonies were screened by
western blot for the expression of Flag-TRF2. Colonies
#1 and 3# were found to be negative and positive, respect-
ively. In the present study, these cells are respectively been
used as the HT1080-TRF2 and HT1080-Vector cells.
Transfection of HeLa cells
HeLa cells were cultured in DMEM supplemented with
10% fetal bovine serum and 100 U/ml penicillin/strepto-
mycin. Subconﬂuent cells were transiently transfected
by transferrin-facilitated lipofection, as described previ-
ously (47). Cells were transiently transfected with no
plasmid (Mock), pcDNA3.1 (empty vector), pcDNA3.1-
Flag-TRF2, pcDNA3.1-Flag-TRF2
B, pcDNA3.1-Flag-
TRF2
B(R361P), pcDNA3.1-Flag–TIN2 or with both
pcDNA3.1-Flag–TIN2 and pcDNA3.1-TRF2
B. Forty-
eight hours post-transfection, cells were harvested for
preparation of whole cells extracts (WCE) or nuclear
extracts (NE).
Preparation of nuclear extracts and whole-cell extracts
Cell extracts were prepared following a modiﬁcation of a
previously published method (12). Forty-eight to
seventy-two hours following transfection, cells were
washed in cold phosphate-buffered saline (PBS) and
resuspended in ﬁve packed-cell volumes of hypotonic buf-
fer (10mM Tris–HCl pH 7.6, 0.5mM EDTA, 1mM DTT,
1mM microcystin-LR, and 1% (v/v) protease inhibitor
cocktail). Cells were allowed to swell on ice for 20min
and then lysed in a Dounce homogenizer using an
A-type pestle until >90% of cells had released their
nucleus. For whole-cell extracts (WCE), an equal
volume of high salt buffer (hypotonic buffer containing
1.2M KCl) was added and the samples were rocked at
4 C for 30min. After centrifugation at 20000g for
30min (Sorvall SL-50T rotor at 12 900rpm), supernatants
were harvested and dialyzed at 4 C for 3h against the
storage buffer (20mM Tris–HCl pH 7.4, 20% glycerol,
0.2mM EDTA, and 10mM b-mercaptoethanol).
Dialyzed samples were cleared by centrifugation
(12000g for 10min), aliquoted, and stored at  80 C.
For nuclear extracts (NE), cell lysates obtained after
douncing were spun at 2500rpm for 5min in an
Eppendorf centrifuge to collect nuclei, which were then
resuspended in 3ml of buffer S1 (0.25M Sucrose, 5mM
Tris–HCl pH 7.4, 1mM DTT, 10mM MgCl2) and
overlaid on top of a sucrose cushion made of buffer S2
(0.35M Sucrose, 5mM Tris–HCl pH 7.4, 1mM DTT,
0.5mM MgCl2). After spinning at 3500rpm for 5min
(Rotor 221), the supernatant was carefully removed and
the isolated nuclei resuspended in ﬁve pellet volumes of
hypotonic buffer (as above). An equal volume of high-salt
buffer (as above) was added and the samples were rocked
at 4 C for 30min. Remaining steps were as described for
the WCE.
Preparation of [
32P]-labeled probes
Primers and templates for synthesis of each probe are
described in Table 1. Probes 4M-30, 4M-bl, 4M-50 and
probes listed in Supplementary Figures S2A, S3A and
S6A were made in a two-step process (as depicted in
Supplementary Figure S1). In the ﬁrst step, a [
32P]-
labeled primer was annealed to a single-stranded
template and extended with Taq DNA polymerase. In
20ml of forward reaction buffer (10mM MgCl2,5 m M
DTT and 70mM Tris–HCl, pH 7.6), 30pmol of the ap-
propriate primer were labeled for 15min at 37 C with
75mCi of g-[
32P]-ATP (3000Ci/mmole) and 10 Units of
T4 polynucleotide kinase (Invitrogen). Following heat in-
activation, this labeling reaction was added to 80mlo f
PCR mix (20mM Tris–HCl, 50mM KCl, 200mMo f
each dNTP, 1.5mM MgCl2, pH 8.4) containing 10pmol
of the single-stranded DNA template. After 95 C for
3min, Taq DNA polymerase (5U) was added and the
primer extended for 5min each at 72 C and then 65 C.
Next, the extension product was puriﬁed using
GENECLEAN Glass Milk (Qbiogene, Irvine, CA, USA)
following the manufacturer’s instructions. In the second
step, the puriﬁed products were digested with outside
cutters PpiI, HgaI or MlyI to produce probes ending re-
spectively with a 30-overhang, 50-extension, or blunt end.
Probes 4M-bl and 4M-50 shared the same template but
were cut with MlyI and HgaI, respectively. After diges-
tion, probes were puriﬁed by native gel electrophoresis on
an 8% polyacrylamide gel and the eluted probes were
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Piscataway, NJ, USA). Probes D4 and D4-nTel
(Figure 4B) were made in the same way, with exception
that the extended product did not require enzymatic di-
gestion to produce a 30-overhang.
Probes listed in Figures 3A and C, 5A and
Supplementary Figure S5A were made by the annealing
of a [
32P]-labeled bottom oligo (Bot) to a 2-fold excess of
an unlabeled top oligo (Top). Labeling of the bottom
oligos was performed as described above, except that the
20ml kinase reactions contained 15pmol of oligo. After
heat inactivating the kinase, the top oligo was added
(30pmol) and the two strands were annealed in a PCR
machine, performing 95 C for 3min and the following
steps for 1min each: 72 C, 65 C, 60 C, 55 C, 50 C,
45 C and then 25 C. After annealing, probes were
puriﬁed by native gel electrophoresis on an 8% polyacryl-
amide gel and the eluted probes were desalted on a G50
spun column (GE Healthcare).
The molarity of each probe was calculated based on the
speciﬁc activity of the radiolabeled oligo with which each
probe was made. To measure the speciﬁc activity of this
oligo, a 2ml aliquot of the heat-inactivated kinase reaction
(containing either 1.5 or 3pmol of oligo) was spotted onto
a DE81 anion exchange paper (Whatman International,
Maidstone, England) and dried for 10min. After washing
away the unincorporated [
32P]-ATP three-times for 5min
each in 50ml of 0.5 M Na2HPO4 (pH 6.8), the remaining
radioactivity was measured by scintillation and the results
expressed in cpm/pmoles (range was 0.4–1.2 10
6 cpm/
pmol). Once puriﬁed, EMSA probes were spotted onto a
DE81 ﬁlter, dried, and counted by scintillation. The
molarity of each probe was calculated based on the
counts and speciﬁc activity of its corresponding primer.
Probes were diluted to 60nM and stored at  20 C.
Electrophoretic mobility shift assay
In a ﬁnal volume of 20ml, reactions contained 4mlo f5 X
binding buffer (20% glycerol, 5mM MgCl2, 5mM DTT,
250mM NaCl, 50mM Tris–HCl pH 7.5), 2mgo f
sonicated Escherichia coli DNA, and 5ml of either NE
or WCE. After 5 min at room temperature, 5 10
4 cpm
of radiolabeled probes were added (probe concentrations
ranging from 2 to 4nM). Reactions were incubated for an
additional 25min, after which point protein/DNA
complexes were resolved by native gel electrophoresis.
When performing supershift experiments, antibodies
were always added for the last 5min of incubation, prior
to the electrophoresis. Depending on the application, elec-
trophoresis took place on either a 4% polyacrylamide gel
or a composite gel made of a 0.5% agarose/2.5% poly-
acrylamide mixture, with the gel containing either TAM
(40mM Tris–acetate, 2mM MgCl2, pH 8.3) or TBE
(45mM Tris–borate, 2mM EDTA, pH 8.3) buffer. Gels
were run at 180 volts for 2 (TBE) to 3h (TAM) at
4 C. Gels were subsequently transferred to a DE81
anion exchange chromatography paper (Whatman
International), dried, and exposed to a PhosphoImager
screen.
Composite gels were made of 0.5% agarose reinforced
by the presence of 2.5% polyacrylamide. Gels were made
based on modiﬁcations of a previously published protocol
(48). To make a composite gel in TAM buffer, 0.3g
of Seakem Gold Agarose (Lonza, Rockland, ME, USA)
is melted in 30ml of TAM buffer and kept at 55 C.
In TAM buffer, a 5% acrylamide solution
Table 1. Oligonucleotides used for making the longer EMSA probes
4M-3'     5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAACCCTAACCCTAACCCTAACCCTAACATGGTCATAGCTGTTTCC-3’  
4M-bl/5'  5’-GGCATGTGAACAGTCGCGACGCGAGTCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACATGGTCATAGCTGTTTCC-3’ 
2M-3'     5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAACCCTAACCCTAATGAGGTCGTGCACATGGTCATAGCTGTTTCC-3’
0M-3'     5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAATGAGGTCGTGCAAGACTCATGCTTCATGGTCATAGCTGTTTCC-3’
M2-3'   5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAATGATAACCCTAATGAGGTCGTGCACATGGTCATAGCTGTTTCC-3’
M2-M4-3'  5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAATGATAACCCTAATGATAACCCTAACATGGTCATAGCTGTTTCC-3’
M4-3'     5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAATGAAGTTGAAGTTGATAACCCTAACATGGTCATAGCTGTTTCC-3’
M2-M4-m'  5’-GGCATGTGAACAGTCGCTCAGGATCAGCAGTGGATCGTGATAACCCTAACCCTAACCCTAACATGGTCATAGCTGTTTCC-3’ 
M13 primer                                                                                                                                        3’-GTACCAGTATCGACAAAGG-5’* 
2R-3' (BrdU)                      *5’-GACTCATTAGGGTTAGGGTTAGGG(BrdU)TAGCTGATCCTGAGCGACTGTTCATGGTCATAGCTGTTTCC-3’ 
M13 primer                                                                                               3’-GTACCAGTATCGACAAAGG-5’ 
D4   5’-TGCTTAGGGTTAGGGTTAGGGTTAGGGTTACACGCATCGTACGAGTTAGGGTTAG-3’ 
D4-nTel  5’-TGCTTAGGGTTAGGGTTAGGGTTAGGGTTACACGCATCGTACGACACTGATGCAT-3’ 
TMS primer                                                                3’-ATGTGCGTAGCATGCT-5’* 
J   5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAATGAAGTTGAGTGCAAGACTCACGGTGAACTTGAG-AAGTCATGGCTGTTGCC-3’ 
MJ   5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAACCCTAATGATCGGATGTGCAAGACTCATGCTGAG-AAGTCATGGCTGTTGCC-3’
MMJ   5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAACCCTAACCCTAATGAGTGCAAGACTCATGCTGAG-AAGTCATGGCTGTTGCC-3’
MM-21-J  5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAATGAAGTTGAGTGCAAGACTCATAACCCTAACCCT-AAGTCATGGCTGTTGCC-3’
iMM-21-J  5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAATGAAGTTGAGTGCAAGACTCATTAGGGTTAGGGTTAAGTCATGGCTGTTGCC-3’
iMM-21-Jmt 5’-GGCATGTGAACAGTCGCTCAGGATCAGGATTCGATGGTGAAGTTGAGTGCAAGACTCATTAGGGTTAGGGTTAAGTCATGGCTGTTGCC-3’ 
M-21-MJ  5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAACCCTAATGAGTGCAAGACTCATGCTGATAACCCT-AAGTCATGGCTGTTGCC-3’
iM-21-MJ  5’-GGCATGTGAACAGTCGCTCAGGATCAGCTAACCCTAACCCTAATGAGTGCAAGACTCATGCTGATTAGGGTTAAGTCATGGCTGTTGCC-3’
M13MS primer                                                                                                                                                                                 3’-TTCAGTACCGACAACGG-5’* 
Shaded areas are telomeric DNA repeats. Recognition sites for PpiI (single line), HgaI (double line) and MlyI (dotted line) are
underlined. Asterisks denote location of the [
32P]-phosphate group. Primers are positioned and oriented as they would if annealed to
their templates.
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transferred to 55 C. To help keep the agarose and acryl-
amide solutions and the casting mold at 55 C, we used a
hybridization oven set to 55 C. After mixing the two so-
lutions, 60ml of TEMED and 600ml of 10% ammonium
persulfate are added and the mixture is immediately
stirred and poured into a casting mold, pre-warmed at
55 C, with 1.5mm spacers. Two identical combs of a
thickness of 0.75mm each are inserted together and in
registry to create wells with a thickness of 1.5mm. After
inserting the two combs, the gel is allowed to solidify hori-
zontally for 1h at 4 C. Next, the bottom spacer is
removed and the gap ﬁlled with 4% agarose in TAM
buffer. This plug is needed to support the gel after the
plates are mounted vertically. To remove the combs, the
middle comb (sandwiched between the outside comb and
the back plate) is ﬁrst removed, leaving the outside comb
in place to prevent the wells from collapsing. Then, the
second comb is freed by pushing it against the back plate
and sliding it out slowly. Next, the gel is mounted verti-
cally onto an electrophoresis apparatus, in our case a
Model V16 apparatus by Gibco BRL (Invitrogen).
Finally, the tanks are ﬁlled with ice-cold TAM buffer,
the apparatus is transferred to the cold room, and the
wells are cleared of remaining gel using a syringe. After
pre-running the gel at 180 volts for 30min, the EMSA
samples are loaded and the gel is allowed to run for an
additional 3h.
Immunoprecipitation of Shelterin/DNA complexes
In a ﬁnal volume of 50ml, reactions contained 10mlo f
5 binding buffer (as described above in the EMSA
section), 5mg of sonicated E. coli DNA, and 12.5mlo f
either NE or WCE. After 5min at room temperature,
1.25 10
5 cpm of radiolabeled probes were added
(probe concentrations ranging from 2 to 4nM).
Reactions were incubated for an additional 25min, after
which protein/DNA complexes were captured with
magnetic beads coated with the M2 anti-Flag antibody.
Ten microliters of M2-coated beads were added and the
suspension was rotated at room temperature for an hour.
Using a magnet, beads were recovered and washed three
times with 500ml of ice-cold 1  binding buffer containing
0.1% BSA (1  buffer as in the EMSA section). In some
experiments, the amount of probe co-precipitated with the
captured complexes was counted by scintillation, with the
results expressed as the percent of each probe recovered
(Mean±SD, n=3). In other experiments, the captured
complexes were subsequently released by incubation of the
beads with 50ml of 3XFLAG peptide (100mg/ml in 1 
binding buffer). After 10min at room temperature, the
eluted complexes were harvested and subsequently
resolved by electrophoresis on composite gels containing
TAM buffer. When performing supershift experiments,
the eluted complexes were allowed to incubate with the
antibodies for 5min prior to the electrophoresis.
Antibody-coated beads were prepared by mixing 200ml
of M-450 magnetic beads coated with a Sheep anti-Mouse
IgG antibody (Dynal Biotech. Inc., Lake Success, NY,
USA) with 15mg of anti-Flag antibody (M2 mouse
monoclonal, Stratagene) in 5ml of PBS containing 0.1%
each of NP-40 and BSA. After overnight rotation at room
temperature, M2-coated beads were washed three times,
after which beads were suspended and stored in 200mlo f
the same buffer. Before use, beads were washed three
times with ice-cold 1  binding buffer containing 0.1%
BSA.
Saturation binding curves
Experiments were performed as described above with the
exception that binding reactions were made to contain
increasing amounts of [
32P]-labeled probes, either D4 or
D4-nTel. Probe concentrations were increased in 1.5- to
3-fold increments from 50 pM to 10nM. Probe concentra-
tions >10nM could not be tested due to limitations of the
methodologies used for probe preparation. Binding reac-
tions (50ml) were made to contain 12.5ml of WCEs from
Flag–TIN2 transfected HeLa cells. Capture was per-
formed with magnetic beads coated with the anti-Flag
M2 antibody or with normal mouse IgG. After washing
the beads three times with 500ml each of ice-cold binding
buffer, the amount of radioactivity captured was counted
by scintillation. The amount of probe recovered in femto-
moles (based on the speciﬁc activity of each probe) was
plotted as a function of total probe concentration
(in pM). The resulting curves were ﬁtted by non-linear
regression to a one-site saturation binding curve
(Probe recovered=Bmax[probe]/(KD+[probe])). Fitting,
performed using SigmaPlot version 11.0, allowed calcula-
tion of the dissociation constant (KD) and maximum
number of binding complexes (Bmax).
RESULTS
Detection of the DNA binding activity of
TRF2-containing Shelterin complex T2
In our initial attempts at detecting the DNA binding
activity of Shelterin complexes, radiolabeled telomeric
DNA fragments (Figure 1A) were incubated in extracts
of HeLa cells previously transfected with TRF2 or
TRF2
B, a mutant that lacks the N-terminal basic
region (Figure 1B–C). This mutant had previously been
reported to exhibit increased binding to ds-telomeric
DNA (9). Initially, protein/DNA complexes were
resolved by electrophoresis in native polyacrylamide gels
containing TBE buffer (Tris–Borate–EDTA). Under these
electrophoretic conditions, species exhibiting properties of
Shelterin complexes were not initially observed (data not
shown). But in gels containing TAM buffer (Tris–
Acetate–Mg
2+), a new complex was detected following
transfection of Flag-tagged TRF2
B (Figure 1D, top
panel, lane 1 versus 2). Unexpectedly, this new complex,
designated as T2, associated with probes that possessed a
30-telomeric overhang (4M-30, lanes 2) but not with probes
carrying either a blunt end (4M-bl, lane 3) or 50-telomeric
extension (4M-50, lane 4). With magnetic beads coated
with an anti-Flag antibody, this complex T2 was
captured, eluted with an excess of 3XFLAG peptide,
and then resolved onto another TAM gel. As the lower
panel of Figure 1D shows, the puriﬁed complexes could
Nucleic Acids Research, 2011,Vol.39, No. 21 9211B
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Figure 1. Transfected Flag-TRF2
B forms a complex that binds selectively to telomeric DNA fragments that carry a 30-overhang. (A) Graphical
representation of probes 4M-30, 4M-bl and 4M-50. Shaded areas represent telomeric DNA. The probes carried four binding sites for the Myb domain
of TRF2 (ds-TTAGGGTTA motifs numbered 1–4) followed by different end structures: 30-telomeric overhang (4M-30), blunt (4M-bl) or 50-telomeric
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(continued)still distinguish between probes carrying the different end
structures. This ability of TRF2
B complexes to select
ligands based on the overhang was unanticipated,
because deletion of the N-terminal basic region should
have eliminated the recently described ss-DNA binding
domain of TRF2 (40). Accordingly, we then reasoned
that TRF2
B must have interacted with other cellular
components, one of which able to recognize ss-DNA.
One possibility was that complex T2 was a Shelterin
complex, with its POT1 subunit mediating recognition of
the 30-telomeric overhang.
In Shelterin complexes, TIN2 is a central component
that couples TRF1 and TRF2 with the ss-DNA binding
activity of the TPP1/POT1 dimer. To determine if TIN2
was an essential component of complex T2, experiments
were repeated with TRF2
B(R361P), a TRF2
B protein
carrying a mutation in its TIN2-interacting domain (49)
(Figure 1B; aa 350–367). In TAM gels, complex T2 was
detected following transfection of Flag-TRF2
B but not
after Flag-TRF2
B(R361P) (Figure 1C, E), thereby sug-
gesting that the interaction with TIN2 is required for for-
mation of the complex. Using an anti-TIN2 antibody, we
then asked if TIN2 could be detected as a component of
the complex. For these experiments, an HT1080 cell line
expressing a Flag-tagged full-length TRF2 was made
(HT1080-TRF2 cells). In these cells, total TRF2 was six
times higher than in the control HT1080-Vector cells
(Figure 2A). Incubating probe 4M-30 with extracts of
HT1080-TRF2 cells led to the detection of complex T2,
as observed by EMSA in TAM gels (Figure 2B; lanes 3–8).
Again, the complex failed to associate with probes lacking
a3 0-telomeric overhang, such as 4M-50 (lane 1) or 4M-bl
(lane 2). Most signiﬁcantly, complex T2 was supershifted
by the TIN2 antibody (lane 6) as well as the Flag antibody
(lane 4). Yet, neither the normal mouse IgG (lane 5) nor
two other unrelated antibodies (lanes 7 and 8) could
supershift the complex. These results along with the
effects of the R361P mutation identiﬁed TIN2 as an im-
portant component of complex T2.
In Shelterin complexes, TRF2 and POT1 are connected
by a protein bridge made of the TIN2 and TPP1 proteins
(11,13–18). If T2 is a Shelterin complex, then the
knockdown of TIN2, TPP1 or POT1 should block forma-
tion of the complex. Our results shown in Figure 2C are in
agreement with this prediction. In HT1080-TRF2 cells
transfected with the non-targeting siRNA, complex T2
was detected (lane 2). The complex was supershifted by
the Flag antibody (lane 9) and interacted with probe
4M-30 (lanes 8–10) but not with probe 4M-bl lacking a
30-overhang (lane 7). In Figure 2C, formation of this
complex was blocked by the separate knockdown of
TIN2 (lane 3), TPP1 (lane 4) or POT1 (lane 5). In these
Shelterin-depleted samples, the activity of complex T2 was
decreased to a level comparable (POT1-depleted) or even
lower (TIN2- and TPP1-depleted) than in the
HT1080-Vector cells (lane 1). In contrast, knocking
down TRF1 did not reduce the activity of complex T2,
thereby suggesting that TRF1 is either absent from the
complex or not required for DNA binding (lane 6). To
conﬁrm the effectiveness of the siRNA treatments, we
employed real-time PCR. As shown in Figure 2D, the
siRNA targeting TIN2, TPP1, POT1 and TRF1 were
found to have reduced the levels of their target mRNAs
by 5.8-, 19.1-, 4.7- and 6.0-fold, respectively. Yet, none of
these siRNAs affected the levels of either the TRF2 or
GAPDH mRNA. These results indicate that T2 is a
Shelterin complex and show that formation of the
complex requires the presence of TIN2, TPP1 and
POT1, but not TRF1.
DNA binding speciﬁcity of complex T2
Next, we deﬁned the DNA binding speciﬁcity of complex
T2 using HT1080-TRF2 extracts as a source of complexes.
In Figure 3A–B, we show that with probes carrying two
Myb sites, extending the size of the overhang to 11 bases
produces a more than 10-fold increase in afﬁnity
(Figure 3B, probe C2 versus A2 and B2). Extending the
overhang also made the interaction with complex T2
stable enough to allow detection in TBE gels (data not
shown). This increase in binding/stability was consistent
with POT1 mediating the recognition of the 30-overhang.
Maximum binding to POT1 requires a 50-TTAGGGTTA
G-30 motif, which POT1 recognizes by means of its two
OB-folds, OB1 and OB2 (8,42,43). OB1 recognizes 50-TTA
GGG and accounts for most of the interactions whereas
OB2 binds to the terminal TTAG-30 (43). Consistent with
a role for POT1, point mutations designed to reduce rec-
ognition of the overhang by OB1 (C2-mOB1, lane 9), OB2
(C2-mOB2, lane 10) or both domains of POT1
(C2-mOB1/2, lane 11) signiﬁcantly reduced the afﬁnity
Figure 1. Continued
overhang (4M-50). [
32P]-phosphate was at the 50-end of the top strand. (B) TRF2 constructs used in transient transfection. Full-length TRF2 contains
a basic domain that binds ss-DNA independently of sequence (Basic), a TRF homology region (TRFH/Dimerization) that serves as dimerization
interface, a domain of interaction with TIN2 (aa 350–367), and a Myb domain that binds to ds-TTAGGGTTA (Myb). Interaction with TIN2 allows
the recruitment of TRF2 in Shelterin complexes. In these complexes, TPP1 and TIN2 act scaffolds linking TRF2 to the ss-DNA binding protein
POT1, which binds to 50-TTAGGGTTAG-30. TRF2
B lacks amino acids 2-44 containing the sequence-independent ss-DNA binding domain of
TRF2. TRF2
B (R361P) contains an additional mutation that blocks the association of TRF2
B with TIN2. All constructs were tagged at the
N-terminus with the Flag epitope. (C) Western blot analysis of HeLa cells transiently transfected with the different TRF2
B constructs. Whole cell
extracts prepared for EMSA (50mg) were probed with the anti-Flag M2 antibody. (D) Transfected TRF2
B is in a complex that binds selectively to
telomeric DNA fragments carrying a 30-overhang. Top panel: WCEs from mock-transfected (lane 1) and TRF2
B-transfected HeLa cells (lanes 2–4)
were incubated with the indicated [
32P]-probes (4M-30, 4M-blunt, 4M-50) and the protein/DNA complexes that formed were resolved by electro-
phoresis in TAM buffer. T2, TRF2-containing complex T2. NS, non-speciﬁc band. Bottom panel: after incubation of the extracts with the indicated
probes, protein/DNA complexes containing Flag-TRF2
B were captured using magnetic beads coated with an anti-Flag antibody, were eluted with
an excess of 3XFLAG peptide, and were subsequently resolved by electrophoresis in TAM buffer. (E) Effects of R361P mutation on formation of
complex T2. HeLa cells were mock-transfected or transfected with Flag-TRF2
B or Flag-TRF2
B(R361P). WCEs were prepared and incubated with
probe 4M-3’, after which point protein/DNA complexes were resolved by electrophoresis in a native polyacrylamide gel containing TAM buffer.
Complex T2 failed to be detected in extracts of HeLa cells transfected with the R361P mutant.
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Figure 2. Complex T2 formed by Flag-tagged TRF2 is a member of the Shelterin family. (A) Western blot analysis of HT1080-TRF2 and
HT1080-Vector cells. WCEs prepared for EMSA (50mg each) were analyzed by western blotting to detected total TRF2 (anti-TRF2 antibody)
and the stably transfected Flag-TRF2 (anti-Flag M2 antibody). Membranes were re-probed with an antibody against b-actin. (B) Complex T2
formed by Flag-TRF2 contains the Shelterin scaffolding component TIN2. Extracts of HT1080-TRF2 cells were incubated with the indicated probes,
9214 Nucleic Acids Research, 2011,Vol.39, No. 21
(continued)of these probes to complex T2. Next, we determined that
binding did not require the immediate proximity of the
junction between ds- and ss-DNA (ds/ss-junction). In
previous probes, this junction was right next to the
POT1 site (ss-TTAGGGTTAG-30). In probe C2-nJunc,
we repositioned the POT1 site at the end of a longer
overhang, six bases away from the ds/ss-junction. This
modiﬁcation did not reduce binding but rather had the
opposite effect (C2-nJunc, lane 12), perhaps by making
the overhang more readily available to POT1. After
that, we extended the bottom strand to create probe
C2-Fork, a forked DNA structure that carried the POT1
site. Consistent with the known ability of POT1 to asso-
ciate with telomeric DNA bubbles (50), complex T2 ex-
hibited strong binding to this probe as well (C2-Fork, lane
13). Taken together, these results show that the presence
of a functional POT1 site is required for the detection of
the interaction of complex T2 with DNA. Finally, we also
performed cross-linking experiments with a radiolabeled
telomeric DNA junction that carried a photoactivatable
BrdU base in its 30-telomeric overhang (Supplementary
Figure S2A–B). After UV cross-linking, immunopre-
cipitation of Flag-TRF2
B complexes and SDS–PAGE
electrophoresis, a cross-linked protein of the same size as
POT1 (74kDa) was detected (Supplementary Figure S2C).
Cross-linking of this protein was not observed in either
the mock-transfected cells or cells transfected with the
Flag-TRF2
B(R361P) mutant. This result supports the
hypothesis that POT1 is the subunit of complex T2 that
mediates the recognition of the 30-telomeric overhang.
To deﬁne the ds-DNA requirements for complex T2
binding, probes that contained variable numbers of Myb
sites (ds-TTAGGGTTA) were tested. Starting with probes
carrying an overhang of 5 bases only, HT1080-TRF2
extracts were subjected to EMSA in TAM gels. No differ-
ence in complex T2 afﬁnity was noted for probes carrying
4 Myb sites or just 2 sites (Supplementary Figure S3A–B).
Yet, removing one or the other Myb site from a probe that
contained two of these sites abrogated complex T2
binding, thereby indicating that two such sites were
required for binding (Supplementary Figure S3A–B).
However, much different results were obtained with
probes that carried a full POT1 site. Starting with probe
C2 containing two Myb sites (Figure 3C), we made de-
rivatives carrying one site (probe C1a), the other site
(probe C1b), or no Myb site (probe C0). In TAM gels, a
complex T2 was detected in HT1080-TRF2 cell extracts
incubated with probe C2 (Figure 3D, lanes 3–5) but not
probe C0 (lane 8). Probe C1a (lane 6) exhibited less than a
2-fold decrease in binding compared to the C2 probe
(Figure 3E). Probes C1b, whose single Myb site was
located closer to the 30-overhang, had a much lower
afﬁnity for complex T2 (lane 7, Figure 3E). These results
show that when a fully functional POT1 site is present, a
single appropriately positioned Myb site is sufﬁcient to
mediate binding to complex T2.
Composition and DNA binding speciﬁcity of Flag–TIN2
complexes
The apparent low afﬁnity of complex T2 for telomeric
DNA molecules lacking a POT1 site (Figure 3B,
C2-mOB½) was unexpected. So we reasoned that the
EMSA conditions may have been too stringent to allow
binding mediated by TRF2 alone. To address this possi-
bility, we wanted to measure DNA binding under condi-
tions that did not require electrophoretic migration in a
speciﬁc buffer. Extracts of Flag–TIN2 transfected HeLa
cells were incubated with the radiolabeled probes and the
Shelterin/DNA complexes that formed were captured
using the anti-Flag antibody (Figure 4A). The amount
of radioactive DNA recovered was then used as a
measure of the afﬁnity of the Flag–TIN2 complexes for
each probe (Figure 4A, left arm) (Results of Figures 4E,
5B, 5C). As a ﬁrst step towards using this assay, EMSA
was employed to characterize the composition of the
immunoprecipitated complexes (Figure 4A, right arm).
After incubation of probe D4 (Figure 4B) with an
extract of Flag–TIN2 transfected HeLa cells, Shelterin/
DNA complexes were immunoprecipitated, eluted with
an excess of 3XFLAG peptide, and analyzed by EMSA.
Prior to loading the gel, the eluted complexes were
incubated with antibodies against each of the Shelterin
subunits. As Figure 4C shows, a radiolabeled complex
was recovered by the antibody from an extract of Flag–
TIN2 transfected cells (lane 1) but not from the
Mock-transfected cells (lane 2). Most importantly, the
captured complex was supershifted by antibodies against
TIN2 (lane 4), TPP1 (lane 5), TRF2 (lane 7), RAP1 (lane
8) and POT1 (lane 9) but not by the normal IgG (lanes 3
and 6). These results conﬁrm that the captured complexes
were members of the Shelterin family. Shelterin complexes
have been proposed to exist in several forms depending on
Figure 2. Continued
after which point protein/DNA complexes were resolved by native electrophoresis in a composite gel containing TAM buffer. Five minutes prior to
loading, the indicated antibodies were added to samples in lanes 4–8 (1mg each of anti-Flag M2 antibody, normal mouse IgG, or antibodies against
TIN2, c-Fos, or Vimentin). Short arrow indicates positions of the supershifted complex T2. NS, non-speciﬁc band. (C) Loss of Shelterin components
prevents formation of complex T2. HT1080-TRF2 cells were transiently transfected with siRNA smartpools against TPP1, TIN2, POT1 or TRF1 or
with non-targeting (NT) siRNA. Nuclear extracts prepared from HT1080-Vector cells (Vector) or from HT1080-TRF2 cells (TRF2) transfected with
the different siRNA were incubated with probe 4M-30, after which protein/DNA complexes were separated by native electrophoresis in composite gel
containing TAM buffer. As expected, complex T2 was more abundant in cells expressing Flag-TRF2 (lane 1 versus 2), was selective for telomeric
DNA fragments that carried a 30-overhang (lane 7 versus 8), and was supershifted by the anti-Flag antibody (lane 9 versus 10). Complex T2 was
reduced in HT1080-TRF2 cells transfected with siRNA smartpools directed against TIN2, TPP1 or POT1 (lanes 3–5 versus lane 2). Short arrow
indicates positions of the supershifted complex T2. NS, non-speciﬁc band. (D) Relative abundance of the TPP1, TIN2, POT1 and TRF1 mRNA in
the siRNA-transfected cells. For each transfection, abundance of the targeted mRNA was measured by real-time PCR, comparing cells transfected
with the targeting and non-targeting (NT) siRNA. For each mRNA, abundance in cells treated with the non-targeting siRNA was set to 1. To show
that targeting was speciﬁc, TRF2 and GAPDH mRNAs were also measured, both of which found to be unaffected by the different siRNA
treatments.
Nucleic Acids Research, 2011,Vol.39, No. 21 9215the presence of TRF1 alone, TRF2 alone or both factors
(10,12,17,20–25). Figure 4D shows that the isolated
complexes were supershifted by both the TRF1 and
TRF2 antibodies (Left panel; lanes 3 and 4). The
antibodies against TRF2 (lane 4) and RAP1 (lane 5)
supershifted almost all of the puriﬁed complexes,
whereas the anti-TRF1 antibody supershifted only half
of the complexes (lane 3). These results indicate that
more than half of these complexes contained both TRF1
and TRF2 as part of the same complex. In contrast, a T2
complex recovered from HT1080-TRF2 cells by
immunoprecipitation of the Flag-TRF2 protein was
supershifted by antibodies against TRF2 (lane 9) and
RAP1 (lane 10) but not by the anti-TRF1 antibody
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Figure 3. Characterization of the DNA binding speciﬁcity of complex T2. (A and C) Graphical representations of the structures of all probes tested.
Probes were designed to harbor different end structures and to contain different number of ds-TTAGGGTTA motifs. Shaded areas represent
telomeric DNA. (B) DNA binding by complex T2 requires a functional POT1 binding site. Probes described in A were incubated with no
extracts (lane 4) or with nuclear extracts of HT1080-Vector (lane 5) or HT1080-TRF2 cells (lanes 1–3 and 6–13), after which point the protein/
DNA complexes were resolved by native electrophoresis in composite gels containing TAM buffer. Five minutes prior to loading, antibodies were
added to samples in lanes 7 (anti-Flag M2 antibody) and 8 (Normal mouse IgG). Lanes 1–3 were overexposed to allow detection of the signal of
probe A2. Short arrow indicates positions of the supershifted complex T2. (D) DNA binding by complex T2 requires at least one Myb binding site.
Probes described in C were incubated with no extracts (lane 1) or with nuclear extracts of HT1080-Vector (lane 2) or HT1080-TRF2 cells (lanes 3–8),
after which point the protein/DNA complexes were resolved by native electrophoresis in composite gels containing TAM buffer. Five min prior to
loading, antibodies were added to samples in lanes 4 (anti-Flag M2 antibody) and 5 (Normal mouse IgG). Short arrow indicates positions of the
supershifted complex T2. (E) Densitometric quantiﬁcation of the T2/DNA complexes detected in (D).
9216 Nucleic Acids Research, 2011,Vol.39, No. 21(lane 8), thereby conﬁrming the absence of TRF1 in this
complex (Figure 4D, right panel).
Next, we performed saturation binding experiments to
quantify the difference in afﬁnity conferred by the POT1
site, and measured this difference in the context of probes
containing an excess of Myb binding sites. To achieve this,
we compared probes D4 and D4-nTel, both of which
containing 4 Myb sites (Figure 4B). Extracts of Flag–
TIN2 transfected HeLa cells were incubated with
increasing concentrations of each probe (from 50 to
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32P]-probe D4. Protein/DNA complexes containing the Flag-tagged proteins were
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of the supershifted Shelterin/DNA complex. (E) Saturation binding curve of the interaction of Flag–TIN2 complexes with probe D4. Extracts of
HeLa cells transfected with Flag–TIN2 were incubated with increasing concentrations of probes D4 or D4-nTel, after which point Flag–TIN2
complexes were recovered with beads coated with either the anti-Flag antibody (M2 Ab) or normal mouse IgG (normal IgG). Scattered plot shows
the amount of probe recovered (in fmoles) as a function of the initial probe concentration (pM). Dotted line shows ﬁtting of the data to either a
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Nucleic Acids Research, 2011,Vol.39, No. 21 92175400 pM), after which the protein/DNA complexes were
immunoprecipitated with the anti-Flag M2 antibody. In
two separate experiments, plotting the amount of probe
recovered as a function of the total probe concentration
revealed a saturable number of binding sites for probe D4
(Figure 4E and data not shown). Non-linear regression
to a one-site saturation binding curve allowed for the
calculation of the dissociation constant (KD). The
apparent KD of the Flag–TIN2 complexes for probe
D4 was calculated to be in the low nanomolar range
(Exp 1: 1.5nM; Exp 2: 1.3nM). With probe D4-nTel,
detectable binding above the background required
much higher concentrations of probe, all above the KD
value of probe D4 (Figure 4E, data not shown). Probe
D4-nTel binding increased linearly up to the highest con-
centration of probe tested (5400 pM) with no evidence of
saturation. These results show that if Shelterin complexes
bind to probe D4-nTel, they do so with a KD at least one
order of magnitude higher than with probe D4. These
results reiterate the strong preference of Shelterin
complexes for telomeric DNA molecules that carry a
functional POT1 site.
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Flag-tagged protein/DNA complexes were captured with the M2 antibody and the amount of radioactivity recovered was counted. Results in
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DNA binding using the Flag–TIN2 pulldown assay. In
triplicates, each of the probe listed in Figure 5A were
co-precipitated with Flag–TIN2 present in HeLa cell
extracts and the amount of radiolabeled probe recovered
was counted (Figure 5B). Overall, the results almost per-
fectly reﬂected those obtained by EMSA for complex T2
(Figure 3A–D). Probe C2 containing a POT1 site and two
Myb sites was recovered efﬁciently from the cells trans-
fected with Flag–TIN2 (C2 in Flag–TIN2) but not from
the mock-transfected cells (C2 in Mock). The same efﬁ-
cient recovery was observed for probes C1a and C1b, both
of which carrying a POT1 site but lacking one or the other
Myb site. Under these immunoprecipitation conditions,
even probe C0 containing no discernible Myb site ex-
hibited a detectable, albeit reduced, binding activity. But
again, probes that did not possess a functional POT1 site
(C2-blunt, C2-nTel or C2-mOB½) showed no evidence of
binding. Nonetheless, efﬁcient recovery was again
observed for probes C2-nJunc and C2-Fork, both of
which containing a functional POT1 site. In Figure 5C,
we repeated these experiments with cells co-transfected
with TRF2
B as a mean of maximizing the DNA
binding activity of TRF2. Again, probe C2 was efﬁciently
recovered only when Flag–TIN2 was present
(TRF2
B+Flag–TIN2 extracts) and not from extracts
lacking the tagged protein (TRF2
B extracts).
Co-transfection of TRF2
B with Flag–TIN2 increased
probe recovery by 4- to 5-fold (Figure 5C) compared to
cells transfected with Flag–TIN2 alone (Figure 5B). But
overall, the DNA binding speciﬁcity of the complexes
were largely unaffected by the presence of TRF2
B.A s
Figure 5C shows, optimal binding required a functional
POT1 site and at least one of the Myb sites (as in probes
C2, C1a, C1b, C2-Junk and C2-Fork). These results re-
iterate the strong preference of Shelterin complexes for ds/
ss-telomeric DNA junctions that carry a binding site each
for POT1 and the Myb domain of TRF1 or TRF2.
DISCUSSION
With radiolabeled probes containing ds/ss-telomeric junc-
tions, we were able to detect the DNA binding activity of
Shelterin complexes in cell extracts. Using these and other
probes, we have deﬁned the composition and DNA
binding speciﬁcity of these complexes. Our results
describe the properties of two Shelterin sub-complexes
that differ in the presence or absence of TRF1, and both
of these complexes were determined to have a strong pref-
erence for DNA fragments that contain both ss- and
ds-telomeric DNA. More speciﬁcally, high afﬁnity
binding was found to require a binding site each for
POT1 (ss-TTAGGGTTAG) and the Myb domain of
either TRF1 or TRF2 (ds-TTAGGGTTA). This DNA
binding speciﬁcity would be expected to recruit these
complexes to areas of the telomere where ss- and
ds-telomeric DNA are in close proximity, such as the
30-overhang, DNA bubbles and the D-loop at the base
of T-loops.
In extracts of cells transfected with Flag-TRF2, a
Shelterin complex was detected by mean of its binding
to a radiolabeled telomeric DNA junction. This complex
was supershifted with antibodies against TIN2, TRF2 and
RAP1 but not by an anti-TRF1 antibody, which we know
can shift TRF1-containing complexes (Figures 2B and
4D). Moreover, the activity of the complex was abrogated
by the knockdown of TIN2, TPP1 and POT1 but was
unaffected by the loss of TRF1 expression (Figure 2C).
These results are consistent with the interpretation that
this complex contains the TRF2, RAP1, TIN2, TPP1
and POT1 proteins. Hence, this complex could be
described as a Shelterin sub-complex that contains
TRF2 but lacks TRF1. A tentative model for the structure
of this T2 complex, based on the current literature, is pre-
sented in Figure 6A. The model proposes a 5-member
complex that contains a dimer of TRF2, its associated
RAP1 subunits, and one molecule each of TIN2, TPP1
and POT1.
An unexpected ﬁnding was the more than 10-fold higher
level of complex T2 activity in cells transfected with TRF2
(Figures 1D, E, 2C, 3B, D and Supplementary Figure
S3B). We did not anticipate that transfection of one
subunit alone, TRF2, would sufﬁce to increase the
activity of the complex if the other subunits are
required. A recent report by Takai et al. (24) provides a
plausible explanation to these observations. If in total cell
extracts TRF2, RAP1 and TIN2 are in vast molar excess
compared to TPP1 and POT1, this apparently is not true
of the soluble protein fraction not bound to chromatin. As
it turns out, TRF1 and TRF2 are almost exclusively
associated with the chromatin, most likely due to their
direct binding to DNA, with virtually none detected in
the soluble fraction (24). As a consequence, this soluble
fraction is rich in RAP1, TIN2, TPP1 and POT1 but lacks
TRF1 and TRF2. Under these conditions, transfection of
an exogenous TRF2 could potentially saturate all DNA
binding sites, causing the excess TRF2 to accumulate in
the soluble fraction where the factor could interact with
RAP1, TIN2, TPP1 and POT1 to form T2 complexes. If
correct, this model would predict that the transfection of
TRF1, like TRF2, should lead to dramatic increases in
Shelterin DNA binding activity, in this case by the accu-
mulation of TRF1/TIN2/TPP1/POT1 sub-complexes. In
agreement with this prediction, large increases in
Shelterin DNA binding activity were also observed follow-
ing TRF1 transfection but not after the transfection of
RAP1 or TPP1 (Supplementary Figure S4). Evidence for
the occurrence of separate sub-complexes containing
TRF1/TIN2/TPP1/POT1 or TRF2/RAP1/TIN2/TPP1/
POT1 have also been observed after deletion or inhibition
of TRF2 or TRF1 (10,12,17,20–25). However, an unre-
solved question is whether these sub-complexes would
also be present in cells expressing physiological levels of
TRF1 and TRF2. Additional studies will be needed to
address this question, but when we compared the DNA
binding speciﬁcity of complex T2 with that of the larger
6-member complex, no signiﬁcant differences were
observed (Figures 3A–D versus 5A–C).
Our second approach to investigate the binding
properties of Shelterin complexes was to quantify the
Nucleic Acids Research, 2011,Vol.39, No. 21 9219amounts of radiolabeled DNA probes co-precipitated
with Flag–TIN2 containing complexes (Figure 4A).
TIN2 is a central component of Shelterin complexes but
the factor could also be part of other undescribed DNA
binding complexes. Performing saturation binding curves
with telomeric DNA fragments with and without a POT1
site determined that Flag–TIN2 complexes possess both a
low-afﬁnity and a high-afﬁnity DNA binding activity
(Figure 4E). The high-afﬁnity activity required the
presence of a POT1 site and displayed apparent Kd
values (1.3 to 1.5nM) that were lower than those previ-
ously reported for POT1, TRF1 or TRF2 alone (39,43).
Characterization of this high-afﬁnity activity by EMSA
indicated that it was attributable to Shelterin complexes
(Figure 4C–D). After co-precipitation with [
32P]-labeled
ds/ss-telomeric junction, the high-afﬁnity complexes were
released by incubation with the Flag peptide. Once
analyzed by EMSA, the eluted complexes were
supershifted by antibodies against TRF1 and TRF2 as
well as antibodies for TIN2, RAP1, TPP1 and POT1.
Antibodies against TIN2, TRF2 and RAP1 supershifted
all of the puriﬁed complexes, whereas those against TRF1,
TPP1 and POT1 supershifted only a fraction of the
complexes. Could this result suggest that some of the
complexes are missing TRF1 or the TPP1/POT1
heterodimer? Not necessarily, as some of the antibodies
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Figure 6. Modeling the interactions of Shelterin complexes with ds- and ss-telomeric DNA. (A) Simultaneous interactions of Shelterin complexes
with both ds- and ss-telomeric DNA. Binding of these multi-subunit complexes to DNA requires a binding site for POT1 (50-TTAGGGTTAG-30)
and at least one binding site for the Myb domains of either TRF1 or TRF2 (ds-TTAGGGTTA motif). Once bound to telomeric DNA, other Myb
domains present in the complexes could further stabilize the protein/DNA complex by establishing additional contacts with ds-telomeric DNA. B)
Implications of this model on the role(s) played at telomeres by the Shelterin complexes. The DNA binding speciﬁcity of Shelterin complexes would
be expected to recruit these complexes to regions of telomeres where ss- and ds-telomeric DNA are present in close proximity, including the
30-telomeric overhang (i), telomeric DNA bubbles (ii), and the D-loop at the base of T-loops (iii). At these locations, Shelterin complexes would
be ideally positioned to control the accessibility of the 30-telomeric overhang (i) to telomerase and T-loop forming machinery. Unoccupied Myb
domains in complexes bound to the 30-telomeric overhang could potentially be available to mediate long-range interactions with upstream
ds-telomeric DNA (dotted arrow). These long-range interactions could help initiate the formation of T-loops. Finally, through their simultaneous
interactions with both ds- and ss-telomeric DNA, Shelterin complexes could help stabilize pre-existing D-loops and T-loops (iii) as well as telomeric
DNA bubbles (ii). Stabilization of these bubbles could promote T-loop formation if the stabilized bubbles are persisting long enough to have a
chance to collide with the 30-telomeric overhang.
9220 Nucleic Acids Research, 2011,Vol.39, No. 21may have lacked the required afﬁnity to produce complete
supershifts. This must have been the case of the TPP1 and
POT1 antibodies, since binding by the puriﬁed complexes
was still very much dependent on the presence of a binding
site for POT1. In the pulldown assays, for instance, probe
recovery was most dramatically affected by the loss of the
30-telomeric overhang—whether deleted, converted to
non-telomeric DNA, or point mutated to block recogni-
tion by POT1 (Figure 5A–C). Most signiﬁcantly, loss of
the POT1 site eliminated binding by most, if not all, of the
immunoprecipitated complexes. These results are consist-
ent with the interpretation that these complexes are made
of a TRF2/RAP1/TIN2 core complex in association with
the TPP1/POT1 heterodimer, with at least half of these
complexes also containing TRF1. In the present literature,
Shelterin complexes are often depicted as containing a
dimer each of TRF2 and TRF1, both interacting simul-
taneously with TIN2 to produce a 6-member complex. In
cells transfected with Flag–TIN2, at least half of the
Shelterin complexes co-precipitated with Flag–TIN2 had
properties consistent with those of the 6-member complex
(Figure 4D).
Using the EMSA and pulldown assays, we have
characterized the DNA binding speciﬁcity of complex T2
and of the Flag–TIN2 complexes, respectively. In both
assays, the presence of a binding site for POT1 was
determined to be an absolute requirement for high-afﬁnity
binding. A complete loss of binding afﬁnity resulted from
the loss of this site, whether deleted, converted to
non-telomeric DNA, or point mutated to block recogni-
tion by POT1 (Figures 3A–B and 5A–C). In contrast, the
distance between this site and the ds/ss-junction could be
changed with little effects on binding. In 80% of native
telomeres, this junction is positioned 2 bases upstream of
the ﬁrst POT1 (Supplementary Figure S5A) (51). In most
of our probes, this spacing was only of one nucleotide and
in probe C2-nJunc, the spacing was of seven bases (Figure
3A). Both probes were recognized with high afﬁnity by the
Shelterin complexes (Figures 3B, 5B–C). Similar results
were obtained in experiments that varied spacing from 1
to 2, 4 or 7 bases (Supplementary Figure S5A–B). Finally,
we also have examined the requirements for the presence
of Myb sites. Not as stringent as for the essential POT1
site, these requirements were found to vary depending on
the assay. Under the conditions of the pulldown assay, a
single Myb site was necessary and sufﬁcient for
high-afﬁnity binding (Figure 5A–C). Binding afﬁnity was
only marginally higher when two sites were present,
whereas the loss of all Myb sites reduced binding signiﬁ-
cantly. Nonetheless, probe C0 containing no discernible
Myb sites still displayed a low but detectable level of
activity. This residual activity might represent binding
mediated by POT1 alone or alternatively, might be due
to the occurrence in probe C0 of a cryptic Myb site.
Under the conditions of the EMSA assay, a single Myb
site was also determined to be necessary and sufﬁcient
for binding, but the location of this site was critical
(Figure 3C–D). Binding was signiﬁcantly lower when the
single Myb site was closest to the 30-telomeric overhang,
possibly due to steric hindrance caused by the proximity of
the Myb and POT1 sites. At native telomeric junctions,
where the complex would always ﬁnd an appropriately
positioned Myb site, a single Myb domain would therefore
be expected to sufﬁce in providing stable binding. Taken
together, data from the two assays show that Shelterin
complexes bind preferentially to ds/ss-DNA junctions
that contain a POT1 binding site (ss-TTAGGGTTAG)
and at least one site for the Myb domain of TRF1 or
TRF2 (ds-TTAGGGTTA). If many of these complexes
contain a multitude of Myb domains, then clearly, occu-
pancy of all of these domains is not required for
high-afﬁnity binding to DNA. Once these complexes are
bound to a telomeric junction, then the other Myb
domains could potentially be available to interact with
distant sites, and, in the process, promote the looping of
the telomere.
For the recruitment of Shelterin complexes, the
telomere could be depicted as offering both lower- and
higher-afﬁnity binding sites. Internal tracks of telomeric
repeats, which likely serve as anchor for a variety of
complexes, would offer an excess of the lower afﬁnity
sites. At these sites, Shelterin complexes would likely
compete for binding with a number of other TRF1/
TRF2-containing complexes. Based on our ﬁndings, telo-
meres would also offer a limited number of higher-afﬁnity
sites. At these sites, Shelterin complexes would be expected
to be more stably bound, thus spending more time on
DNA before falling off. It should be noted that more
stable pools of telomeric complexes have been reported
previously for TRF2. In these photo-bleaching experi-
ments, two distinct pools of TRF2 were noted at the telo-
meres (52). One fraction exchanged rapidly (residence time
of  44s) but a second smaller fraction was far more stable
with dynamics similar to POT1 (residence time of
 11min). It may be that this second fraction was part
of Shelterin complexes that were bound to higher
afﬁnity sites. How many of these higher afﬁnity sites are
likely to be present at the telomere? The ds/ss-junction
next to the 30-telomeric overhang would certainly create
one such site (Figure 6B; i). At this location, a Shelterin
complex would be optimally positioned to perform many
of its key functions. There, the complex could control the
availability of the 30-telomeric overhang to telomerase,
T-loop forming machinery, and DNA damage sensing
mechanisms (RPA/ATR, ATM). And since we show
that junction binding requires no more than one Myb
domain, then the other such domains in an already
bound complex could potentially be available to interact
with other upstream sites and, in the process, loop the
telomere to initiate T-loop formation (Figure 6B; dotted
arrow). High-afﬁnity binding sites might also be present at
other telomeric substructures if they contain ds- and
ss-telomeric DNA in close proximity to each other. In
follow-up experiments, we have examined the ﬂexibility
with which high-afﬁnity binding sites are recognized by
Shelterin complexes. Starting with a telomeric DNA
junction carrying a sub-optimal POT1 site, we varied the
orientation and distance separating the POT1 site and two
Myb sites (Supplementary Figure S6A). Surprisingly,
binding took place with little constraints on either
distance or orientation (Supplementary Figure S6B), a
capability likely made possible by the long and ﬂexible
Nucleic Acids Research, 2011,Vol.39, No. 21 9221hinge region of TRF1 and TRF2. With this ﬂexibility,
other high-afﬁnity sites could potentially be recognized
at the base of T-loops, within the displacement loop
(Figure 6B; iii). This D-loop consists of ss- and
ds-telomeric DNA ﬁbers that run parallel to each other.
Interacting simultaneously with the two ﬁbers, Shelterin
complexes could lock the D-loop in its current conform-
ation, and in so doing, stabilize the T-loop. In Figures 3B,
5B and C, we show that Shelterin complexes can interact
with forked DNA junctions, which are structures that may
exist as part of telomeric DNA bubbles. Bubbles that form
in duplex telomeric DNA as a result of DNA breathing or
biochemical activities (TRF2-induced supercoiling, DNA
helicases) could therefore provide other high afﬁnity sites
(Figure 6B; ii). By stabilizing these bubbles, Shelterin
complexes could promote T-loop formation if the
bubbles are stabilized long enough to collide with the
30-telomeric overhang.
In the present report, we have developed assays with
which to measure the DNA binding activity of Shelterin
complexes in human cell extracts. Our results indicate that
these complexes bind preferentially to DNA fragments
that contain a binding site each for POT1 and the Myb
domain of TRF1 or TRF2. This binding speciﬁcity is pre-
dicted to recruit these complexes to areas of the telomere
where ss- and ds-DNA are in close proximity, such as the
30-telomeric overhang, telomeric DNA bubbles and the
D-loop at the base of T-loops. At these locations,
Shelterin complexes would be ideally positioned to
control the access of telomerase to telomeres as well as
promote the formation and stability of T-loops.
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